The Medical University of South Carolina   Medical Center  ·  College of Medicine ·  Directory   
Department of Pathology Banner MUSC Logo


Our Mission

To serve patients, health care providers, research scientists, scholars, and society by providing excellence and innovation in diagnostic services and educational resources in a respectful, professional and culturally diverse atmosphere.

Our Vision

To become a preeminent leader in academic anatomic and clinical pathology while translating basic science discovery to improved clinical care.



Victoria J. Findlay, Ph.D.

Victoria J. Findlay, Ph.D.

Assistant Professor, Department of Pathology & Laboratory Medicine
Department of Pathology & Laboratory Medicine
Office: Hollings Cancer Center Room 343

EDUCATION:

BSc (Hons) Biochemistry - Heriot-Watt University, Edinburgh, Scotland, UK
Ph.D. Biochemistry & Genetics – University of Newcastle upon Tyne, England, UK

RESEARCH INTERESTS:

MicroRNAs (miRNAs) are Endogenous 19-25 nucleotide RNAs that have recently emerged as a novel class of small, evolutionarily conserved gene regulatory molecules involved in many critical developmental and cellular functions. Mounting evidence indicates that miRNAs may also play a significant role in cellular transformation and carcinogenesis acting either as oncogenes (oncomirs) or tumor suppressors. The importance of miRNAs in cancer progression has been established, however the role of specific miRNAs is lacking. We have shown that miR-204 & -510 are elevated in human breast and prostate tumor samples when compared to normal tissue. Our research interests include defining miR-204 and miR-510 as ‘oncomirs’ and to identify and validate their downstream targets.

AWARDS & MEMBERSHIPS:

Abney Foundation Scholars Committee Member 2008

SELECTED PUBLICATIONS:

  1. DP Turner, VJ Findlay, AD Kirven, O Moussa and DK Watson. Global gene expression analysis identifies PDEF regulatory circuits during metastatic progression. Mol Biol Cell, in press 2008.
  2. VJ Findlay, DP Turner, O Moussa and DK Watson. miRNA-mediated regulation of PDEF in breast cancer. Cancer Research, in press 2008.
  3. DP Turner, VJ Findlay, O Moussa and DK Watson. Defining ETS transcription regulatory networks and their contribution to breast cancer progression. J Cell Biochem, 102(3): 549-559, 2007.
  4. VJ Findlay, DM Townsend, TE Morris, et al. A novel role for human sulfiredoxin in the reversal of glutathionylation, Cancer Res, 66(13): 6800-6806, 2006.
  5. DM Townsend, VJ Findlay and KD Tew. Sulfiredoxin. AfCS-Nature Molecule Pages (2006). (DOI:10.1038/mp.a003958.01)
  6. JE Saavedra, A Srinivasan, GS Buzard, KM Davies, DJ Waterhouse, K Inami, TC Wilde, ML Citro, M Cuellar, JR Deschamps, D Parish, PJ Shami, VJ Findlay, et al. PABA/NO as an anticancer lead: Analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity, J Med Chem, 49(3): 1157-1164, 2006.
  7. DM Townsend, VJ Findlay, F Fazilev, et al. A glutathione S-transferase p activated pro-drug causes kinase activation concurrent with S-glutathionylation of proteins, Mol Pharmacol, 69(2): 501-508, 2006.
  8. VJ Findlay, DM Townsend and KD Tew. Glutathione and glutathione S-transferase as targets for anticancer drug development. In: Toxicology of Glutathione S-Transferases. Ed. Awasthi, Y. Taylor and Francis Books, Inc., Boca Raton, FL. pp155-178, 2006.
  9. VJ Findlay, DM Townsend and KD Tew. Glutathione and glutathione S-transferases in drug resistance. In: Drug Resistance in Oncology. Ed. Teicher, B. pp2313-2322, 2006.
  10. VJ Findlay, H Tapiero and DM Townsend. Sulfiredoxin: a potential therapeutic target? Biomedicine & Pharmacotherapy, 59(7): 374-379, 2005.
  11. DM Townsend, VJ Findlay and KD Tew. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol, 401: 287-307, 2005.
  12. SM Bozonet, VJ Findlay, AM Day, et al. Oxidation of a eukaryotic 2-Cys peroxiredoxin is a molecular switch controlling the transcriptional response to increasing levels of hydrogen peroxide. J Biol Chem, 280: 23319-23327, 2005.
  13. EA Veal*, VJ Findlay*, AM Day, et al. A eukaryotic 2-Cys peroxiredoxin is required for peroxide signaling. Mol Cell, 15: 1-20, 2004. *Both authors contributed equally to this work.
  14. VJ Findlay, DM Townsend, JE Saavedra, GS Buzard, ML Citro, LK Keefer, X Ji and KD Tew. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Mol Pharmacol, 65: 1070-1079, 2004
  15. Amonafide, Nelfinavir, Nevirapine, Ritonavir, Faslodex, Herceptin, Arsenic Trioxide, Rapamycin and Tositumomab, Victoria J. Findlay and Kenneth D. Tew, XPharm (2004); Executive Editors: S.J. Enna and David B. Bylund; Publisher, Elsevier Inc., New York.
  16. KD Tew, JT Boyd, ZJ Chen, W Davis, F Fazilev, VJ Findlay, L Gaté, KE Ile, A Soulika and DM Townsend. Glutathione and ABC transporters as determinants of sensitivity to oxidative and nitrosative stress. J Nutr Sci, 134: 3205S-3206S, 2004.
  17. DM Townsend, L Gate, VJ Findlay, et al. Glutathione S-Transferase P1-1. In Alliance for Cellular Signaling. Website and Nature Publishers, 2002.
  18. J Quinn, VJ Findlay, K Dawson, et al. Distinct regulatory proteins control the graded transcriptional response to increasing H2O2 levels in fission yeast Schizosaccharomyces pombe, Mol Biol Cell, 13: 805-816, 2002.
  19. SJ Ross, VJ Findlay, P Malakasi, et al. Thioredoxin peroxidase is required for the transcriptional response to oxidative stress in budding yeast, Mol Biol Cell, 11: 2631-2642, 2000.


Pathology Divisions
Anatomic Pathology
Laboratory Medicine
Research

Department of Pathology and Laboratory Medicine Chairman Dr. Steven L. Carroll
Message from the Chairman


News


Upcoming Events


Copyright 2011 MUSC Department of Pathology and Laboratory Medicine